Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion

Myc, Andrzej; Kukowska-Latallo, Jolanta F.; Bielinska, Anna U.; Cao, Peter; Myc, Piotr P.; Janczak, Katarzyna; Sturm, Tracy R.; Grabinski, Michael S.; Landers, Jeffrey J.; Young, Katherine S.; Chang, Joseph; Hamouda, Tarek; Olszewski, Michal A.; Baker, James R.

doi:10.1016/s0264-410x(03)00381-5

Cited by 85 publications

(71 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have previously demonstrated that these NEs have broad antimicrobial activity (3,17) and are safe and effective noninflammatory mucosal adjuvants for a whole-virus-based influenza vaccine (36). NEs in the present studies are simply mixed with rPA and applied to the nares of mice and guinea pigs for characterization of anti-PA immune responses.…”

mentioning

confidence: 88%

Mucosal Immunization with a Novel Nanoemulsion-Based Recombinant Anthrax Protective Antigen Vaccine Protects againstBacillus anthracisSpore Challenge

et al. 2007

Self Cite

View full text Add to dashboard Cite

The currently available commercial human anthrax vaccine requires multiple injections for efficacy and has side effects due to its alum adjuvant. These factors limit its utility when immunizing exposed populations in emergent situations. We evaluated a novel mucosal adjuvant that consists of a nontoxic, water-in-oil nanoemulsion (NE). This material does not contain a proinflammatory component but penetrates mucosal surfaces to load antigens into dendritic cells. Mice and guinea pigs were intranasally immunized with recombinant Bacillus anthracis protective antigen (rPA) mixed in NE as an adjuvant. rPA-NE immunization was effective in inducing both serum anti-PA immunoglobulin G (IgG) and bronchial anti-PA IgA and IgG antibodies after either one or two mucosal administrations. Serum anti-PA IgG2a and IgG2b antibodies and PA-specific cytokine induction after immunization indicate a Th1-polarized immune response. rPA-NE immunization also produced high titers of lethal-toxin-neutralizing serum antibodies in both mice and guinea pigs. Guinea pigs nasally immunized with rPA-NE vaccine were protected against an intradermal challenge with ϳ1,000 times the 50% lethal dose (ϳ1,000؋ LD 50 ) of B. anthracis Ames strain spores (1.38 ؋ 10 3 spores), which killed control animals within 96 h. Nasal immunization also resulted in 70% and 40% survival rates against intranasal challenge with 10؋ LD 50 and 100؋ LD 50 (1.2 ؋ 10 6 and 1.2 ؋ 10 7 ) Ames strain spores. Our results indicate that NE can effectively adjuvant rPA for intranasal immunization. This potentially could lead to a needle-free anthrax vaccine requiring fewer doses and having fewer side effects than the currently available human vaccine.

show abstract

mentioning

confidence: 88%

Mucosal Immunization with a Novel Nanoemulsion-Based Recombinant Anthrax Protective Antigen Vaccine Protects againstBacillus anthracisSpore Challenge

et al. 2007

Self Cite

View full text Add to dashboard Cite

show abstract

“…13 Briefly, the appearance of the fresh and centrifuged (13,000× g for 30 minutes) nanoemulsion vaccine was observed after six cycles (one cycle stored at 4°C for 28 hours and 25°C for 48 hours). The nanoemulsion vaccine is considered unstable if it has different appearances.…”

Section: Thermodynamic Stability Testmentioning

confidence: 99%

Induction of systemic and mucosal immunity against methicillin-resistant Staphylococcus aureus infection by a novel nanoemulsion adjuvant vaccine

Sun¹,

Wei²,

Liu³

et al. 2015

IJN

View full text Add to dashboard Cite

The Gram-positive bacterial pathogen methicillin-resistant Staphylococcus aureus (MRSA) can cause infections in the bloodstream, endocardial tissue, respiratory tract, culture-confirmed skin, or soft tissue. There are currently no effective vaccines, and none are expected to become available in the near future. An effective vaccine capable of eliciting both systemic and mucosal immune responses is also urgently needed. Here, we reported a novel oil-in-water nanoemulsion adjuvant vaccine containing an MRSA recombination protein antigen, Cremophor EL-35 ® as a surfactant, and propylene glycol as a co-surfactant. This nanoemulsion vaccine, whose average diameter was 31.34±0.49 nm, demonstrated good protein structure integrity, protein specificity, and good stability at room temperature for 1 year. The intramuscular systemic and nasal mucosal immune responses demonstrated that this nanoemulsion vaccine could improve the specific immune responses of immunoglobulin (Ig)G and related subclasses, such as IgG1, IgG2a, and IgG2b, as well as IgA, in the serum after Balb/c mice intramuscular immunization and C57 mice nasal immunization. Furthermore, this nanoemulsion vaccine also markedly enhanced the interferon-γ and interleukin-17A cytokine cell immune response, improved the survival ratio, and reduced bacterial colonization. Taken together, our results show that this novel nanoemulsion vaccine has great potential and is a robust generator of an effective intramuscular systemic and nasal mucosal immune response without the need for an additional adjuvant. Thus, the present study serves as a sound scientific foundation for future strategies in the development of this novel nanoemulsion adjuvant vaccine to enhance both the intramuscular systemic and nasal mucosal immune responses.

show abstract

“…W 80 5EC NE contains droplets of approximately 400 nm in diameter and has inherent antimicrobial activity (23). Studies with a prototype NE formulations showed that the NE can inactivate whole influenza virus and induce an immune response after nasal administration that protects mice from homologous influenza virus challenge (25). Similar protective immune responses were observed using the NE with either whole vaccinia virus (VV) (7) or purified antigens such as recombinant anthrax protective antigen (8).…”

mentioning

confidence: 90%

Intranasal Immunization of Ferrets with Commercial Trivalent Influenza Vaccines Formulated in a Nanoemulsion-Based Adjuvant

Hamouda

Sutcliffe

Ciotti

et al. 2011

Clin Vaccine Immunol

Self Cite

View full text Add to dashboard Cite

Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion

Cited by 85 publications

References 32 publications

Mucosal Immunization with a Novel Nanoemulsion-Based Recombinant Anthrax Protective Antigen Vaccine Protects againstBacillus anthracisSpore Challenge

Mucosal Immunization with a Novel Nanoemulsion-Based Recombinant Anthrax Protective Antigen Vaccine Protects againstBacillus anthracisSpore Challenge

Induction of systemic and mucosal immunity against methicillin-resistant Staphylococcus aureus infection by a novel nanoemulsion adjuvant vaccine

Intranasal Immunization of Ferrets with Commercial Trivalent Influenza Vaccines Formulated in a Nanoemulsion-Based Adjuvant

Contact Info

Product

Resources

About